TANDEM DIABETES CARE INC
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
TNDM$18.71+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, and
CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $69,234 | $58,868 |
| Short-term investments | 369,095 | 409,044 |
| Accounts receivable, net | 114,585 | 105,555 |
| Inventories | 149,612 | 157,937 |
| Prepaid and other current assets | 21,965 | 16,585 |
| Total current assets | 724,491 | 747,989 |
| Property and equipment, net | 78,150 | 76,542 |
| Operating lease right-of-use assets | 85,306 | 87,791 |
| Equity method investments | 74,545 | — |
| Other long-term assets | 5,166 | 40,336 |
| Total assets | $967,658 | $952,658 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $44,730 | $49,586 |
| Accrued expenses | 18,170 | 12,726 |
| Employee-related liabilities | 64,128 | 43,430 |
| Current portion of convertible senior notes, net | 40,670 | — |
| Operating lease liabilities | 18,208 | 17,060 |
| Deferred revenue | 11,831 | 43,994 |
| Other current liabilities | 49,312 | 28,462 |
| Total current liabilities | 247,049 | 195,258 |
| Convertible senior notes, net - long-term | 308,266 | 285,035 |
| Operating lease liabilities - long-term | 106,421 | 113,572 |
| Deferred revenue - long-term | 10,455 | 13,331 |
| Other long-term liabilities | 32,369 | 31,830 |
| Total liabilities | 704,560 | 639,026 |
| Commitments and contingencies (Note 13) | — | — |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 200,000 shares authorized, 66,264 and 65,552 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively. | 66 | 66 |
| Additional paid-in capital | 1,312,804 | 1,263,997 |
| Accumulated other comprehensive income (loss) | (1,947) | 1,369 |
| Accumulated deficit | (1,047,825) | (951,800) |
| Total stockholders’ equity | 263,098 | 313,632 |
| Total liabilities and stockholders’ equity | $967,658 | $952,658 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.